Vertex Pharma stock gains as analysts lift targets on solid Q2 figures
Published on 09/18/2026 at 12:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Vertex Pharmaceuticals Incorporated (ISIN US92532F1003) stock traded at USD 516.34 on the Nasdaq as of the closing auction on September 17, 2026, leaving the Vertex Pharma stock roughly 10 percent below the average 12-month analyst price target and close to the upper end of its 52-week range.
Analysts reinforce Moderate Buy stance
According to MarketBeat on September 18, 2026, Vertex Pharma stock currently carries an average recommendation of Moderate Buy from 23 brokerages, with two firms rating the shares Hold, 20 assigning Buy and one issuing a Strong Buy rating.
The same analyst overview cites an average 1-year price objective of USD 570.83 for Vertex Pharmaceuticals, implying roughly 10.5 percent upside versus the last closing price of USD 516.34 on September 17, 2026.MarketBeat Within that, JPMorgan Chase & Co. reaffirmed its Overweight rating on Vertex Pharmaceuticals and raised its target from USD 515.00 to USD 560.00 in a report dated September 11, 2026, adding a concrete bullish signal for the stock.MarketBeat
Q2 2026 results support valuation
Vertex Pharma’s current valuation rests on solid operational momentum. As summarized in a biotech earnings table from MarketBeat, Vertex Pharmaceuticals reported earnings per share of USD 4.73 for the second quarter of 2026, essentially in line with the consensus estimate of USD 4.74 and representing a narrow miss of just USD 0.01 per share.
In the same Q2 2026 period, Vertex Pharma generated revenue of USD 3.33 billion compared with analyst expectations of USD 3.23 billion, beating the consensus by USD 0.10 billion and marking a 12.5 percent increase over the year-ago quarter.MarketBeat The net margin stood at 35.0 percent, underlining the company’s ability to translate sales growth into profits even as it continues to invest in a broad pipeline.
On a trailing-twelve-month basis, Vertex Pharmaceuticals delivered net income of USD 3.95 billion, corresponding to earnings per share of USD 17.18 and a trailing price-to-earnings ratio of about 30.0 at the latest quoted share price.MarketBeat For investors, that multiple is paired with expected earnings per share of 16.69 for the current fiscal year 2026, giving the stock a forward-looking price-to-earnings-growth ratio around 2.25.MarketBeat
Cystic fibrosis portfolio and pipeline remain key drivers
Beyond the numbers, the business profile explains why many analysts see continued upside in Vertex Pharma stock. As outlined in a company description from MarketBeat, Vertex Pharmaceuticals focuses on therapies for cystic fibrosis and other serious diseases, with TRIKAFTA, KAFTRIO, SYMDEKO, ORKAMBI and KALYDECO forming a portfolio of CFTR modulators that target the underlying cause of cystic fibrosis.
The same profile highlights a pipeline that includes VX-522, an mRNA therapeutic designed to address the cystic fibrosis transmembrane conductance regulator defect; VX-548, a non-opioid acute and neuropathic pain medicine in Phase 3; and gene-editing and cell therapy programs such as exa-cel for sickle cell disease and transfusion-dependent beta thalassemia, as well as APOL1-mediated kidney disease and type 1 diabetes candidates.MarketBeat These programs support the growth narrative embedded in the current analyst targets, but they also bring typical biotech risks around clinical trial outcomes and regulatory decisions.
Collaborations with partners such as CRISPR Therapeutics and Moderna broaden Vertex’s technological base in gene editing and mRNA therapeutics, but they add integration and execution risk that investors need to monitor in parallel with the company’s strong cash generation.MarketBeat With a debt-to-equity ratio effectively near zero and a current ratio above 3.0, Vertex appears financially well positioned to fund this pipeline internally, which is one of the reasons why the shares are often viewed as a relatively lower-risk way to participate in biotech innovation.MarketBeat
Stock trades near the top of its 52-week range
In price terms, Vertex Pharma stock is currently closer to its recent highs than its lows. Market data compiled by MarketBeat show that Vertex Pharmaceuticals closed at USD 516.34 on the Nasdaq on September 17, 2026, up 0.60 percent on the day, with the shares trading within a 52-week range of USD 374.17 to USD 560.25.
At that latest closing price, the company’s market capitalization stands at about USD 130.27 billion, underscoring Vertex’s status as one of the larger global biotech names.MarketBeat The shares show a beta of 0.32, meaning that historically the stock has moved significantly less than the broader equity market, a characteristic that may appeal to investors seeking exposure to biotech growth with somewhat lower volatility.
Looking at performance, Vertex Pharma stock has gained 33.37 percent over the past 12 months, while delivering a 14.33 percent advance over the last 90 days as of September 17, 2026, according to the same comparison overview.MarketBeat For investors, the key question is whether the combination of a premium multiple, strong CF cash flows and a pipeline of non-CF programs is sufficient to justify further upside toward or beyond the USD 570.83 consensus price target.
Vertex Pharma stock at a glance
As of the completed trading day on September 17, 2026, the reference price for Vertex Pharma stock is the Nasdaq closing level of USD 516.34 in United States dollars. That closing price aligns with a 52-week interval between USD 374.17 and USD 560.25 and is paired with a market capitalization of approximately USD 130.27 billion at the same date.
Vertex Pharma stock - key data
- Company: Vertex Pharmaceuticals Incorporated
- ISIN: US92532F1003
- Ticker: VRTX
- Trading venue: Nasdaq
- Price (as of September 17, 2026, 16:00): 516.34 USD
- Market capitalization: 130.27 billion USD (as of September 17, 2026)
- Sector / Industry: Biotechnology / Pharmaceuticals
- Index membership: S&P 500
- Next earnings date: November 2, 2026
